Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DermGEN
- Development stage
- Phase 1
- Lead developer
- DeCell Technologies
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Other Cell Types → Cell Therapies, Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Topical
01
Overview
DermGEN is a regenerative tissue matrix derived from decellularized human dermis, designed to provide an optimal healing environment for chronic wounds such as diabetic foot ulcers. The product preserves the natural composition and structure of the extracellular matrix (ECM), which is recognized by patient cells and stimulates a regenerative healing process. By maintaining ECM architecture and relevant growth factors, DermGEN supports rapid vascularization, reduced inflammation, and improved tissue remodeling compared to other grafts. It is sterilized to minimize infection risk and has received approval from Health Canada for use in humans. Developed primarily for wound care—especially diabetic foot ulcers—DermGEN leverages the body's own regenerative capacity to accelerate wound bed integration within one week[2][6].
- Brand names
- DermGEN
- Other names
- DermGEN dermal regeneration scaffold
Beyond the preview
Go deeper on DermGEN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DermGEN.